These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Too few older patients in cancer trials: experts say disparity affects research results and care. Mitka M JAMA; 2003 Jul; 290(1):27-8. PubMed ID: 12837701 [No Abstract] [Full Text] [Related]
27. Patient selection for a curative approach to carcinomatosis. Piso P; Glockzin G; von Breitenbuch P; Sulaiman T; Popp F; Dahlke M; Esquivel J; Schlitt HJ Cancer J; 2009; 15(3):236-42. PubMed ID: 19556910 [TBL] [Abstract][Full Text] [Related]
28. Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2. Italiano A; Fizazi K Eur Urol; 2009 Jun; 55(6):1313-4. PubMed ID: 18849106 [No Abstract] [Full Text] [Related]
29. Advancing the cause for clinical trials with the elderly. Provider; 2004 Feb; 30(2):30-1, 33. PubMed ID: 14964918 [No Abstract] [Full Text] [Related]
30. Chemotherapy options and outcomes in older adult patients with colorectal cancer. Saif MW; Lichtman SM Crit Rev Oncol Hematol; 2009 Nov; 72(2):155-69. PubMed ID: 19356946 [TBL] [Abstract][Full Text] [Related]
31. Pharmacology of antineoplastic medications in older cancer patients. Balducci L Oncology (Williston Park); 2009 Jan; 23(1):78-85. PubMed ID: 19283925 [TBL] [Abstract][Full Text] [Related]
32. The ethics of phase 0 oncology trials. Abdoler E; Taylor H; Wendler D Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585 [TBL] [Abstract][Full Text] [Related]
33. Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? Bruner DW J Clin Oncol; 2007 Dec; 25(34):5345-7. PubMed ID: 18048812 [No Abstract] [Full Text] [Related]
34. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
35. The challenges of clinical trials for adolescents and young adults with cancer. Ferrari A; Montello M; Budd T; Bleyer A Pediatr Blood Cancer; 2008 May; 50(5 Suppl):1101-4. PubMed ID: 18360838 [TBL] [Abstract][Full Text] [Related]
36. [Treatment for recurrent uterine cancer]. Sagae S; Sugimura M; Nagata M Gan To Kagaku Ryoho; 2009 Feb; 36(2):220-3. PubMed ID: 19263610 [No Abstract] [Full Text] [Related]
37. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
38. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
39. Risk-adapted use of intravesical immunotherapy. Braasch MR; Böhle A; O'Donnell MA BJU Int; 2008 Nov; 102(9 Pt B):1254-64. PubMed ID: 19035890 [No Abstract] [Full Text] [Related]
40. Response assessment in clinical trials: implications for sarcoma clinical trial design. Jaffe CC Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]